Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis

Clinical trial condition

Hepatitis

Explore clinical trials studying Hepatitis. Study availability and eligibility vary by location and protocol.

2,967 public trials 189 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis trial results

Completed

Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing

NCT02068963

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Arkansas Gastroenterology North Little Rock, Arkansas, United States

Franco Felizarta, MD Bakersfield, California, United States

Inland Empire Liver Foundation Rialto, California, United States

Kaiser Permanente San Francisco, California, United States

View all 34 locations

View Trial Details

Completed

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

NCT02598063

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Beijing, China

Beijing, China

Beijing, China

Chongqing, China

View Trial Details

Completed

Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection

NCT02355951

Conditions: Blood-Borne Infections, Chronic Disease, Chronic Hepatitis B, +15 more
Locations: Montreal, Canada

Grenoble, France

Lyon, France

Nancy, France

View Trial Details

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: 1241.21.0003 Boehringer Ingelheim Investigational Site La Jolla, California, United States

1241.21.0006 Boehringer Ingelheim Investigational Site San Diego, California, United States

1241.21.0004 Boehringer Ingelheim Investigational Site San Francisco, California, United States

1241.21.0011 Boehringer Ingelheim Investigational Site Palm Harbor, Florida, United States

View all 53 locations

View Trial Details

Completed

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Investigative Site Miami, Florida, United States

Investigative Site San Antonio, Texas, United States

Investigative Site Murray, Utah, United States

Investigative Site Frankfurt, Germany

View Trial Details

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: University Of Alabama At Birmingham Birmingham, Alabama, United States

Scripps Clinic La Jolla, California, United States

Southern California Permanente Medical Group Los Angeles, California, United States

Desert Medical Group Inc. Palm Springs, California, United States

View all 86 locations

View Trial Details

Completed

Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)

NCT01813513

Conditions: Blood-Borne Infections, Chronic Hepatitis C Infection, Communicable Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

NCT01605513

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Phase One Clinical Trial ward, First Hospital, Jilin University Changchun, Jilin, China

View Trial Details

Completed

A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)

NCT01335607

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

NCT01919125

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Not specified

View Trial Details